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Summary The study was designed to identify factors that could predict response to chemotherapy in breast cancer. A total of 173 patients
with measurable or evaluable metastatic breast cancer were enrolled in a randomized trial between November 1987 and January 1991 to
receive a monthly dose of 5-fluorouracil (500 mg m-2), epirubicin (60 mg m-2) and cyclophosphamide (500 mg m-2) either administered in four
weekly doses or in an every-4-week dose as first-line cytotoxic treatment. In 103 evaluable patients we performed a multivariate analysis of
the tumour biological factors, i.e. histological grade, oestrogen receptor (ER), progesterone receptor (PR), S-phase fraction (SPF), ploidy,
p53, c-erbB-2, Bcl-2 and Bax expression, which showed significance in the univariate analysis according to treatment response, time to
progression (TTP) or overall survival (OS). In the univariate analysis only SPF, grade and the proapoptotic protein Bax correlated with the
response to cytotoxic treatment. In the multivariate analysis SPF had the strongest correlation, followed by grade and Bax. In the univariate
analysis grade, PR, Bax and Bcl-2 correlated significantly with TTP, whereas in the multivariate analysis only PR showed a statistically
significant correlation. In the univariate analysis PR and Bax correlated with OS and both retained its significance in the multivariate analysis.
The factors that correlated significantly with the response to cytotoxic treatment in the univariate analysis, i.e. grade, SPF and Bax, seemed
to predict independently the response to treatment in the multivariate analysis also. UTP and OS could be predicted partly by the same
factors, although the association was quite weak. More studies and new tumour biological factors are needed to identify the group of breast
cancer patients who get the most benefit from chemotherapy.
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Identifying factors predicting the response to chemotherapy would
assist the clinician in selecting the right patients for chemotherapy
and saving the rest from unnecessary toxicity. So far, few data
have been presented in the medical literature on this topic. For a
summary ofthe latest data see our recent review article on predic-
tive factors for chemotherapy in advanced breast cancer (Sjostrom
and Blomqvist, 1996). Tumour proliferation rate is the only
tumour biological factor that has consistently been reported to be
ofpredictive value in advanced breast cancer. For other factors no
consensus exists. Recently, some apoptosis (Krajewski et al, 1995)
and drug resistance genes (Ro et al, 1990; Verrelle et al, 1991)
have been correlated with chemotherapy responses, suggesting
their use as new prognostic markers.
We have previously published results on the value of DNA
ploidy and SPF (Hietanen et al, 1995), histological grade, c-erbB-
2, p53 and cathepsin-D (Niskanen et al, 1997), and Bcl-2 and Bax
(Krajewski et al, 1995) to predict chemotherapy response in
metastatic breast cancer. The response to chemotherapy was
significantly better in patients with tumours with a high SPF
(Hietanen et al, 1995). Surprisingly, low-grade tumours responded
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better (Niskanen et al, 1997). C-erbB-2, p53 or cathepsin-D
expression did not predict the treatment outcome. Tumours
expressing the proapoptotic protein Bax responded better to
chemotherapy (Krajewski et al, 1995). The present study reports
the results of a multivariate analysis on the factors that correlated
with the treatment response in the univariate analyses.
MATERIALS AND METHODS
Patients and tumour material
A total of 173 patients with measurable or evaluable metastatic
breast cancer were enrolled in a randomized trial between
November 1987 and January 1991 at the Department ofOncology
of the Helsinki University Central Hospital. Both randomized
groups received a monthly dose of 5-fluorouracil (500 mg m-2),
epirubicin (60 mg m-2) and cyclophosphamide (500 mg m-2)
(FEC), either administered in four weekly doses or once every 4
weeks. Patients with a history of previous cytotoxic treatment for
advanced disease were excluded from the study. The details ofthe
trial have been published (Blomqvist et al, 1993).
Paraffin-embedded blocks for further analysis of biological
markers were available for 130patients. Nine patients were excluded
because of unrepresentative histology (n = 5), presence of other
malignancy (n = 2), early death (n = 1) or histologically unproven
metastasis (n = 1). Additionally, 17 were excluded because of
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Table 1 Characteristics of the tumour at the time of diagnosis
Factor Subgroups No. of patients(%)
Histology 103
Ductal 80 (78)
Lobular 23 (22)
Grade 103
1 22 (21)
2 57 (55)
3 24 (23)
ER 97
Positive 47 (48)
Negative 50 (52)
PR 96
Positive 37 (39)
Negative 59 (61)
SPF 70
Low 34 (49)
High 36 (51)
Ploidy 70
Diploidy 24 (34)
Aneuploidy 46 (66)
p53 103
Negative 86 (83)
Positive 17 (17)
c-erbB-2 103
Low 80 (78)
Intermediate 9 (9)
High 14 (13)
Bcl-2 101
Negative 52 (51)
Positive 49 (49)
Bax 103
Negative 38 (37)
Positive 65 (63)
simultaneous radiotherapy (n = 8), modified chemotherapy regimen
(n = 5), simultaneous endocrine therapy (n = 2) or surgical excision
ofthe only lesion (n = 2). One additional patient was excluded from
this analysis because ofthe histological diagnosis ofmedullary carci-
noma (where grade could not be assessed). In the remaining 103
patients theresponse to chemotherapy couldbe assessed according to
UICC criteria. Ofthe 103 patients included in this study, 55 patients
received FEC on a monthly basis and 48 patients on a weekly basis.
Overall response rate was 38% (complete response 5/55, partial
response 16/55) in the monthly treated patient group and 31%
(complete response 1/48, partial response 14/48) in the weekly
treatedpatient group. Twenty-eight patients had stable disease and 39
patients progressed on treatment. The median follow-up time for 11
surviving patients was 34.7 (range 22.4-66.1) months. All the other
patients were followed up until death.
It was possible to determine SPF and ploidy in 70 tumours. The
characteristics ofthe tumours at the time ofdiagnosis are shown in
Table 1.
Biochemical and immunohistochemical assays
Oestrogen receptor (ER) and progesterone receptor (PR) were
assessed biochemically using the DCC (dextran-coated charcoal)
method. Receptor concentration less than 5 fmol mg-' was consid-
ered negative. Both ductal and lobular carcinomas were histologi-
cally graded by one pathologist (KF) according to the Richardson
Bloom classification modified by Elston and Ellis (1991). The cut-
off point for low and high SPF was 4.2% in diploid tumours and
12.5% in aneuploid tumours (Hietanen et al, 1995), which is the
median of the respective groups in a large series of SPF determi-
nation in our laboratory. p53 immunohistochemical assays were
performed using the D07 (Novocastra) antibody, and we inter-
preted the tumour as positive for p53 overexpression if > 10% of
cells stained positively. C-erb-B2 assays were performed both
immunohistochemically using the NCL-CB11 (Novocastra) anti-
body and by semiquantitative polymerase chain reaction (PCR)
(Niskanen et al, 1997). The stained specimens were interpreted as
negative, slightly positive (< 50% of cells stained positively) or
strongly positive (. 50% of cells stained positively). Bcl-2 and
Bax were assessed immunohistochemically using polyclonal anti-
sera prepared in rabbits, and tumours were scored as negative if
less than 10% of the infiltrating tumours cells were stained
(Krajewski et al, 1994a,b).
Statistical analysis
In the univariate analysis differences in treatment response
according to histological grade, ER, PR, SPF, ploidy, p53, c-erbB-2,
Table 2 The correlation between the investigated tumour biological factors
Factor ER PR Grade SPF Ploidy p53 c-erb-B2 Bcl-2 Bax
ER P<0.001 P = 0.002 NS NS P = 0.04 NS P = 0.003 NS
PR P<0.001 P = 0.005 NS NS NS NS P= 0.003 NS
Grade P= 0.002 P= 0.005 P= 0.04 NS P= 0.006 NS P= 0.03 NS
SPF NS NS P = 0.04 NS NS NS NS NS
Ploidy NS NS NS NS NS NS NS NS
p53 P = 0.04 NS P = 0.006 NS NS NS NS NS
c-erb-B2 NS NS NS NS NS NS NS NS
Bcl-2 P = 0.003 P = 0.003 P = 0.3 NS NS NS NS P = 0.008
Bax NS NS NS NS NS NS NS P=0.008
Of the 46 ER-positive tumours, 30 (65%) were also PR positive, 43 (91%) were p53 negative and 30 (65%) were Bcl-2 positive. Of the 47 ER-positive tumours,
13 (28%) were grade 1, 30 (64%) were grade 2 and 4 (8%) were Grade 3. Of the 36 PR-positive patients, 25 (69%) were Bcl-2 positive. Of the 37 PR-positive
tumours, 11 (30%) were grade 1, 23 (62%) were grade 2 and 3 (8%) were grade 3. Of the 36 high SPF tumours, 4 (11%) were grade 1, 18 (50%) were grade 2
and 14 (29%) were grade 3. Of the 17 p53-positive tumours 1 (6%) was grade 1, 7 (41%) were grade 2 and 9 (53%) were grade 3. Of the 49 Bcl-2-positive
tumours, 37 (76%) were Bax positive, 14 (29%) were grade 1, 28 (57%) were grade 2 and 7 (14%) were grade 3.
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Table 3 Univariate and multivariate analyses of the correlation of a tumour biological factor with cytotoxic treatment outcome
Response Univariate analysis Multivariate analysis (n = 70)
Factor Odds ratio (95% Cl) P-value Odds ratio (95% Cl) P-value
Grade (n = 103) 0.41 (0.21-0.80) 0.01 0.36 (0.14-0.92) 0.04
SPF (n=70) 3.73 (1.24-11.21) 0.02 7.11 (1.89-26.66) <0.01
Bax (n 103) 2.84 (1.13-7.13) 0.03 3.22 (0.96-10.81) 0.06
TTP (n = 96)
Factor Odds ratio (95% Cl) P-value Odds ratio (95% Cl) P-value
Grade (n= 103) 1.61 (1.17-2.21) <0.01 1.38 (0.95-2.00) 0.09
PR (n = 96) 0.53 (0.34-0.82) <0.01 0.58 (0.35-0.96) 0.04
Bax (n= 103) 0.63 (0.42-0.95) 0.03 0.71 (0.45-1.12) 0.71
Bcl-2 (n= 101) 0.65 (0.43-0.98) 0.04 0.91 (0.54-1.51) 0.14
Survival (n = 96)
Factor Hazards ratio (95% Cl) P-value Hazards ratio (95% Cl) P-value
PR (n = 96) 0.61 (0.39-0.97) 0.03 0.58 (0.37-0.93) 0.02
Bax (n = 103) 0.60 (0.40-0.93) 0.02 0.58 (0.37-0.91) 0.02
Bcl-2 and Bax were tested with logistic regression with the response
scored into two groups (complete response + partial response vs no
change + progressive disease). Variables were included in the multi-
variate analysis only if there was a significant association with
response rate in the univariate analysis. Because data were missing
from some patients the multivariate analysis was performed both
including only patients with no missing data or substituting missing
data with mean values. There was no difference between these two
approaches and only the results with actual n-values, i.e. case-wise
calculated, are reported. Inclusion of the treatment group in the
logistic regression multivariate analysis did not change the results.
The univariate analyses of TTP and OS were performed by the
Cox logistic regression model. Only significant factors were tested
in the multivariate analyses. The hazards ratios were also calcu-
lated. The multivariate analyses were also carried out both in the
actual number ofpatients with all analysed values available and by
substitution with mean values, but only the case-wise results are
reported here as there was no significant difference in the results.
Inclusion of the treatment group in the Cox multivariate analysis
did not change the results.
The correlation between tumour biological factors (Table 2) was
tested with the chi-square test when both factors were scored to
two groups: ER, PR, SPF, ploidy, p53, Bcl-2, Bax; with the
Mann-Whitney U-test when one factor was scored to two and the
other to three groups or the Spearman's correlation coefficient test
when both factors were scored to three groups: grade, c-erb-B2.
RESULTS
The correlation between the investigated factors is shown in Table
2. There was a significant correlation between poor differentiation
(high histological grade) and ER and PR negativity, high SPF, p53
staining and absence of Bcl-2 staining. Bax was positively associ-
ated with Bcl-2 staining but not to any other factors. In the
univariate analysis only SPF, grade and Bax correlated with the
response to cytotoxic treatment (Table 3). In the multivariate
analysis all three factors remained significant in association with
treatment response. SPF had the strongest effect, followed by
grade and Bax (Table 3).
In the univariate analysis grade, PR, Bax and Bcl-2 had a signif-
icant effect on time to progression (TTP) (Table 3), whereas in the
multivariate analysis of these factors only PR showed a statisti-
cally significant effect (Table 3).
In the univariate analysis PR and Bax had an effect on overall
survival (OS) and both remained significant in the multivariate
analysis of these two factors also (Table 3).
DISCUSSION
This is the first report on multivariate analysis of the relationship
between tumour biological factors and the outcome of cytotoxic
treatment for metastatic breast cancer.
Factors that significantly predicted response to cytotoxic treat-
ment in the univariate analysis, i.e. grade, SPF and Bax, indepen-
dently predicted the response to treatment also in the multivariate
analysis. SPF was the most powerful predictive factor. Tumours
with high SPF responded better to cytotoxic treatment. This is in
accordance with the results by other investigators (Remvikos et al,
1989). SPF was not associated with TTP or OS either in the
univariate or multivariate analysis, unlike grade and Bax.
However, this does not mean that these patients had no benefit,
because, without a favourable chemotherapy response, patients
with rapidly proliferating tumours typically have a worse
prognosis (Mansour et al, 1994).
Surprisingly, a high histological grade was inversely related to
chemotherapy efficacy, i.e. low-grade tumours responded best to
cytotoxic treatment. The association between high grade and a
poor chemotherapy response is surprising as high grade also asso-
ciates with a high proliferation rate, a factor that in itselfcorrelates
with a favourable response. Also, in our study, there was a positive
correlation between high SPF and grade (P = 0.04). We have no
clear explanation for these results. Two facts indicate that this
result is not due to chance. The association was not only statisti-
cally significant but also consistent through the three grades, i.e.
grade 1 tumours had the best responses, grade 2 intermediate and
grade 3 the worst. Secondly, one other study has also recently
reported a similar finding in patients treated with preoperative
chemotherapy for primary breast cancer (Aas et al, 1996).
We have previously shown that the expression ofthe proapoptotic
protein Bax predicts a better response rate (Krajewski et al, 1995).
The predictive value of Bax was of borderline significance in the
multivariate analyses. The predictive value of Bax can be explained
by the fact that most anti-cancer agents as well as radiation ultimately
kill cancer cells, primarily by inducing apoptosis (Reed, 1994).
In conclusion, we have identified three factors - SPF, grade and
Bax - that independently and significantly predicted response to
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combination chemotherapy in advanced breast cancer. The associ-
ation of SPF and Bax with treatment outcome strengthens the
notion that chemotherapy response is a consequence not only of
direct DNA damage but also of the functional interaction between
drugs and cell cycle regulation as well as the apoptotic pathway.
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